Peer-influenced content. Sources you trust. No registration required. This is HCN.
MDLinx
“The key word is association. This study does not establish causality. For absolute, catastrophic harm to an appropriately selected, monitored pain patient, the risk is small.” – Sean Mackey, MD, PhD, Chief of the Division of Stanford Pain Medicine
Clinical Pharmacology February 6th 2026
Pharmacy Times
This updated indication now allows the use of upadacitinib prior to the use of tumor necrosis factor (TNF) blocking agents in patients for whom use of these treatments is clinically inadvisable and who have received at least 1 approved systemic therapy.
Clinical Pharmacology October 14th 2025
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS